GILEAD SCIENCES, INC. Goodwill, Acquired During Period
GILEAD SCIENCES, INC. (GILD) reported Goodwill, Acquired During Period of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2023-02-22
- GILEAD SCIENCES, INC. goodwill, acquired during period for the quarter ending 2021-12-31 was $0.00.
- GILEAD SCIENCES, INC. goodwill, acquired during period for the quarter ending 2021-09-30 was $0.00.
- GILEAD SCIENCES, INC. goodwill, acquired during period for the quarter ending 2021-06-30 was $0.00.
- GILEAD SCIENCES, INC. goodwill, acquired during period for the quarter ending 2021-03-31 was $226.00M.
- GILEAD SCIENCES, INC. goodwill, acquired during period for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- GILEAD SCIENCES, INC. goodwill, acquired during period for fiscal 2021 was $226.00M, a 94.34% decline from fiscal 2020.
- GILEAD SCIENCES, INC. goodwill, acquired during period for fiscal 2020 was $3.99B.
| Period end | Goodwill, Acquired During Period | Goodwill, Acquired During Period as first filed | Goodwill, Acquired During Period 1 month | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-22 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 derived: sum of 3 quarters · filed 2023-02-22 | $226.00M 10-K · filed 2023-02-22 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $226.00M 10-Q · filed 2021-11-03 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $226.00M 10-Q · filed 2021-08-05 | |||||
| 2021-03-31 | $226.00M 10-Q · filed 2021-05-06 | ||||||
| 2020-12-31 | $3.99B 10-K · filed 2022-02-23 | ||||||
| 2017-10-31 | $2.99B 10-K · filed 2018-02-27 | ||||||
| 2017-10-03 | $2.94B 10-Q · filed 2018-11-06 | $2.99B 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |